Literature DB >> 6894770

Protective effects of aspirin in endotoxic shock.

P V Halushka, W C Wise, J A Cook.   

Abstract

Endotoxic shock is associated with increased metabolism of arachidonic acid to thromboxanes (TX) and prostaglandins (PG). This study assessed the effects of varied doses of aspirin, an inhibitor of arachidonic acid metabolism, on Salmonella enteriditis endotoxin (20 mg/kg)-induced mortality, plasma levels of arachidonate metabolites and other pathophysiological sequelae in Long-Evans rats. Aspirin, in doses of 3.75, 15 an 30 mg/kg, given 30 min before endotoxin significantly (P less than .01) improved 24-hr survival from 11% to 60 to 70%, but 100 mg/kg afforded no protection. Pretreatment with aspirin (15 or 100 mg/kg) 30 min before endotoxin significantly (P less than .001) decreased the endotoxin-induced elevations in plasma levels of immunoreactive (i) TXB2, a stable metabolite of TXA2, i6-keto PGF1 alpha, a stable metabolite of PGI2 and significantly (P less than .05) inhibited thrombin-induced in vitro platelet iTXB2 synthesis. Endotoxin-induced hypoglycemia and elevations in serum acid phosphatase and beta-glucuronidase activities, lysosomal enzymes, were all significantly (P less than .01) attenuated by pretreatment with aspirin (15 mg/kg) 30 min before endotoxin. Aspirin (15 or 100 mg/kg) given 24 h before challenge with endotoxin significantly improved 24-hr survival to 42 (P less than .01) and 44% (P less than .005), respectively. Although 24 hr pretreatment with aspirin (15 or 100 mg/kg) significantly (P less than .001) reduced endotoxin-induced elevations in iTXB2, only the 100 mg/kg dose significantly lowered plasma levels of i6-keto PGF1 alpha. These observations are consistent with the notion that the beneficial effects of aspirin seen in experimental endotoxic shock may be mediated, in part, via reduction of platelet TXA2 synthesis.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6894770

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  11 in total

Review 1.  Manifold beneficial effects of acetyl salicylic acid and nonsteroidal anti-inflammatory drugs on sepsis.

Authors:  Damon P Eisen
Journal:  Intensive Care Med       Date:  2012-04-25       Impact factor: 17.440

2.  Altered functions of platelets during aging.

Authors:  Emilie Montenont; Matthew T Rondina; Robert A Campbell
Journal:  Curr Opin Hematol       Date:  2019-09       Impact factor: 3.284

Review 3.  Prevention or Treatment of Ards With Aspirin: A Review of Preclinical Models and Meta-Analysis of Clinical Studies.

Authors:  Bernardo Amisa Panka; Harm-Jan de Grooth; Angélique Maria Elisabeth Spoelstra-de Man; Mark R Looney; Pieter-Roel Tuinman
Journal:  Shock       Date:  2017-01       Impact factor: 3.454

4.  Effect of dietary alpha-linolenate/linoleate balance on endotoxin-induced hepatitis in mice.

Authors:  S Watanabe; H Okuyama
Journal:  Lipids       Date:  1991-06       Impact factor: 1.880

Review 5.  Role of thromboxane, prostaglandins and leukotrienes in endotoxic and septic shock.

Authors:  H A Ball; J A Cook; W C Wise; P V Halushka
Journal:  Intensive Care Med       Date:  1986       Impact factor: 17.440

6.  Effects of a pyridine derivative thromboxane synthetase inhibitor and its inactive isomer in endotoxic shock in the rat.

Authors:  K Anderegg; P Anzeveno; J A Cook; P V Halushka; J McCarthy; E Wagner; W C Wise
Journal:  Br J Pharmacol       Date:  1983-04       Impact factor: 8.739

7.  Beneficial effects of UK 37248, a thromboxane synthetase inhibitor, in experimental endotoxic shock in the rat.

Authors:  P V Halushka; J A Cook; W C Wise
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

Review 8.  Cyclooxygenase inhibition in sepsis: is there life after death?

Authors:  David M Aronoff
Journal:  Mediators Inflamm       Date:  2012-05-14       Impact factor: 4.711

9.  Effect of aspirin on deaths associated with sepsis in healthy older people (ANTISEPSIS): a randomised, double-blind, placebo-controlled primary prevention trial.

Authors:  Damon P Eisen; Karin Leder; Robyn L Woods; Jessica E Lockery; Sarah L McGuinness; Rory Wolfe; David Pilcher; Elizabeth M Moore; Adithya Shastry; Mark R Nelson; Christopher M Reid; John J McNeil; Emma S McBryde
Journal:  Lancet Respir Med       Date:  2020-09-17       Impact factor: 30.700

Review 10.  Multiple organ dysfunction syndrome.

Authors:  M J Murray; D B Coursin
Journal:  Yale J Biol Med       Date:  1993 Sep-Oct
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.